Emergent BioSolutions | EBS - Acreedores Comerciales





Acreedores Comerciales Cambio Fecha
Acadia Pharmaceuticals USD 12.25M 1.34M 2026-03
Akebia Therapeutics USD 8.39M 12.8M 2026-03
ALKERMES USD 102.36M 5.59M 2026-03
Alnylam Pharmaceuticals USD 126.63M 10.91M 2026-03
Amarin USD 48.15M 2.8M 2026-03
ANI Pharmaceuticals USD 69.69M 7.11M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Coherus Biosciences USD 9.91M 14.98M 2025-12
Emergent BioSolutions USD 112.2M 500K 2023-12
Exelixis USD 24.15M 5.47M 2026-03
Glaxosmithkline GBP 20.72B 346.14M 2025-12
Heron Therapeutics USD 8.97M 24K 2026-03
Ionis Pharmaceuticals USD 26.03M 2.05M 2026-03
Ironwood Pharmaceuticals USD 3.24M 339K 2026-03
Lexicon Pharmaceuticals USD 3M 87K 2026-03
Lonza CHF 471M 3M 2024-12
Merck USD 3.86B 541M 2026-03
Moderna USD 161M 156M 2026-03
Myriad Genetics USD 32.6M 2.6M 2026-03
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Pacira USD 14.01M 1.14M 2026-03
Pfizer USD 4.51B 734M 2026-03
PTC Therapeutics USD 25.48M 20M 2026-03
Sanofi EUR 22.71B 219M 2026-03
Sarepta Therapeutics USD 70.38M 210.46M 2026-03
United Therapeutics USD 498.3M 491.2M 2026-03
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12
Xoma USD 2.65M 1.52M 2025-09